AbbVie announces collaboration agreement with Iambic: Can ABBV break above $266.24?

Traders Union
All News
Business & Wealth
Companies
AbbVie stock is little changed today

Highlights

AbbVie entered a collaboration with Iambic to accelerate the use of AI in drug discovery for immunology, neuroscience and oncology.
AbbVie stock is little changed on the day, trading near $263.78.
98 of 124 analysts rate AbbVie stock a buy, with a median price target of $282, about 6.9% above the current price.

AbbVie announced it has entered a collaboration agreement with Iambic. The partnership is designed to advance the use of artificial intelligence in drug discovery. These AI initiatives will span immunology, neuroscience and oncology.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish setup holds as shares recover early session losses

The session started with a gap down from the previous close at $264.02 to $262.88, with shares of AbbVie recovering part of that drop as the day progressed. Price remains above the MA-20, MA-50, and MA-200, which keeps the overall daily setup looking bullish. The weekly high at $266.24 marks nearby resistance. Stoch RSI is in overbought territory, limiting the room for further upside moves.

Upside odds hold as traders eye a close above the weekly high

To gauge whether recent developments are being incorporated into the price, traders should watch for a close above $266.24 to confirm buyer commitment. Shares opened lower at $262.88 after closing previously at $264.02, but have regained some ground since. The recent move has been contained within a narrow range over the past week; still, from here, the probability of upside is more than 80% and downside risk remains less than 20%, with an expected trading range of $260 to $267.55 for the coming trading week. A close above the weekly high would confirm buyers are stepping in, while a drop below $259.67 would indicate the move is being rejected. On the weekly chart, the longer-term outlook remains firmly constructive.

Earlier, analysts noted that AbbVie was consolidating after recent acquisition activity and positive clinical trial results, with technical setups suggesting a potential shift on a decisive breakout. The latest collaboration with Iambic to drive AI-based drug discovery adds further momentum to AbbVie’s innovation push, and traders should monitor whether a sustained move above $266.24 confirms buyer engagement amid the current bullish trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.